Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Dong, Haidong, Strome, Scott E., Salomao, Diva R., Tamura, Hideto, Hirano, Fumiya, Flies, Dallas B., Roche, Patrick C., Lu, Jun +5 more·2002·Nature Medicine

DOI 10.1038/nm730

Cited by (1,026)

Items 801–900 of 1,026

Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Chan-Young Ock, Jun‐Eul Hwang, Bhumsuk Keam, Sang-Bae Kim, Jae‐Jun Shim, Hee-Jin Jang, Sarang Park, Bo Hwa Sohn, Minse Cha, Jaffer A. Ajani et al. · 2017 · Nature Communications
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ling Ding, Xi Chen, Xiaqing Xu, Yuli Qian, Guikai Liang, Fengqi Yao, Zhangting Yao, Honghai Wu, Jieqiong Zhang, Qiaojun He et al. · 2018 · Cancer Immunology Research
Recent Advances and Challenges in Cancer Immunotherapy
Chelsea M. Peterson, Nathan Denlinger, Yiping Yang · 2022 · Cancers
The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity
Sabelo Lukhele, Diala Abd-Rabbo, Mengdi Guo, Jian Shen, Heidi J. Elsaesser, Rene Quevedo, Madeleine Carew, Ramy Gadalla, Laura M. Snell, Lawanya Mahesh et al. · 2022 · Immunity
Tumor dormancy and cancer stem cells: two sides of the same coin?
S. Kleffel, T. Schatton · 2013 · Advances in Experimental Medicine and Biology
Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes
Terry W. Hermiston, Irene Kuhn · 2002 · Cancer Gene Therapy
Cancer immunotherapy: breaking the barriers to harvest the crop
Drew M. Pardoll, James Patrick Allison · 2004 · Nature Medicine
Soluble Form of T Cell Ig Mucin 3 Is an Inhibitory Molecule in T Cell-Mediated Immune Response
Hui Geng, Guimei Zhang, Dong Li, Hui Zhang, Ye Yuan, Han-gang Zhu, Xiao Han, Lingfei Han, Zuo‐Hua Feng · 2006 · The Journal of Immunology
Melanoma in Immunosuppressed Patients
Agnieszka W. Kubica, Jerry D. Brewer · 2012 · Mayo Clinic Proceedings
Cellular and molecular mechanisms in cancer immune escape: a comprehensive review
Alka Bhatia, Yashwant Kumar · 2013 · Expert Review of Clinical Immunology
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Aaron Scott Mansfield, Stephen J. Murphy, Tobias Peikert, Eunhee S. Yi, George Vasmatzis, Dennis A. Wigle, Marie Christine Aubry · 2015 · Clinical Cancer Research
Increased expression of PD-L1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity
Chaoqi Liu, Jiao Lü, Huiqun Tian, Wei Du, Lin Zhao, Jing Feng, Ding Yuan, Zhiying Li · 2017 · Molecular Medicine Reports
Comprehensive in vitro characterization of PD-L1 small molecule inhibitors
Aravindhan Ganesan, Marawan Ahmed, Isobel Okoye, Elena I Arutyunova, Dinesh Babu, William L. Turnbull, Joydeb Kumar Kundu, Justin A. Shields, Katharine Cheryl Agopsowicz, Lai Xu et al. · 2019 · Scientific Reports
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion
Yingqi Qiu, Tong Chen, Rong Hu, Ruiyi Zhu, Chujun Li, Yingchen Ruan, Xiaoling Xie, Yuhua Li · 2021 · Biomarker Research
Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee, Sheila Spada, Sumit Mukherjee · 2023 · Biology
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Elias, Rawad, Karantanos, Theodoros, Sira, Elizabeth, Hartshorn, Kevan L. · 2017 · Journal of Geriatric Oncology
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non–Small-Cell Lung Cancer
Satoru Kitazono, Yutaka Fujiwara, Koji Tsuta, Hirofumi Utsumi, Shintaro Kanda, Hidehito Horinouchi, Hiroshi Nokihara, Noboru Yamamoto, Shinji Sasada, Shun-ichi J. WATANABE et al. · 2015 · Clinical Lung Cancer
Immunotherapy earns its spot in the ranks of cancer therapy
Drew M. Pardoll, Charles G. Drake · 2012 · The Journal of Experimental Medicine
Role of immune cells in pancreatic cancer from bench to clinical application
Jae Hyuck Chang, Yongjian Jiang, Venu Gopal Pillarisetty · 2016 · Medicine
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh J. Barve, Wei Jin, Yanli Liu, John Fetse, Kun Cheng · 2019 · Journal for ImmunoTherapy of Cancer
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
John David Klement, Priscilla S. Redd, Chunwan Lu, Alyssa D. Merting, Dakota B. Poschel, Dafeng Yang, Natasha M. Savage, Gang Zhou, David H. Munn, Padraic G. Fallon et al. · 2023 · Cancer Cell
Antibiotic use and the efficacy of immune checkpoint inhibitors in cancer patients: a pooled analysis of 2740 cancer patients
Huang, Xuan-Zhang, Gao, Peng, Song, Yong-Xi, Xu, Yan, Sun, Jing-Xu, Chen, Xiao-Wan, Zhao, Jun-Hua, Wang, Zhen-Ning · 2019 · OncoImmunology
Clinical Significance of B7‐H1 and B7‐1 Expressions in Pancreatic Carcinoma
Liancai Wang, Qingyong Ma, Xiangli Chen, Kun Guo, Junhui Li, Min Zhang · 2010 · World Journal of Surgery
CTLA ‐4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Luis H. Camacho · 2015 · Cancer Medicine
Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy
Kui Li, Hongqi Tian · 2018 · Journal of drug targeting
Immunotherapeutic interventions of Triple Negative Breast Cancer
Zehuan Li, Yiran Qiu, Weiqi Lu, Ying Jiang, Jin Wang · 2018 · Journal of Translational Medicine
Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer
Zanwen Zuo, Zerong Zhou, Yuzhou Chang, Yan Liu, Yuping Shen, Qizhang Li, Lei Zhang · 2022 · Genes & Diseases
O -GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation
Qiang Zhu, Hongxing Wang, Siyuan Chai, Liang Xu, Bingyi Lin, Wen Yi, Liming Wu · 2023 · Proceedings of the National Academy of Sciences
B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by Porphyromonas gingivalis
Sabine Elisabeth. Groeger, Eugen Domann, Jose Roberto Gonzales, Trinad Chakraborty, Joerg Meyle · 2011 · Immunobiology
Harnessing the immune system to treat cancer
Nina Bhardwaj · 2007 · Journal of Clinical Investigation
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
David Alan Quigley, Vessela Nedelcheva Kristensen · 2015 · Molecular Oncology
Expression of PD-1 and PD-L1 in thymic epithelial neoplasms
Annikka Weissferdt, Junya Fujimoto, Neda Kalhor, Jaime Rodriguez‐Canales, Roland L. Bassett, Ignacio Ivan Wistuba, César A. Moran · 2017 · Modern Pathology
Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells
Estefanía Paula Juliá, Analía Amante, María Betina Pampena, José Mordoh, Estrella Mariel Levy · 2018 · Frontiers in Immunology
Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment
Laurel B. Darragh, Ayman J. Oweida, Sana D. Karam · 2019 · Frontiers in Immunology
The therapeutic implications of immunosuppressive tumor aerobic glycolysis
Bradley I. Reinfeld, W. Kimryn Rathmell, Tae Kon Kim, Jeffrey C. Rathmell · 2021 · Cellular and Molecular Immunology
NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-H1 that stimulates T cells
Aurore Saudemont, Nathalie Jouy, Dominique Hétuin, Bruno Quesnel · 2004 · Blood
Tumor-Specific Bacteriophages Induce Tumor Destruction through Activation of Tumor-Associated Macrophages
Eriksson, Fredrik, Tsagozis, Panagiotis, Lundberg, Kajsa, Parsa, Roham, Mangsbo, Sara M, Persson, Mats A A, Harris, Robert A, Pisa, Pavel · 2009 · The Journal of Immunology
Immune Checkpoint Protein Inhibition for Cancer: Preclinical Justification for CTLA-4 and PD-1 Blockade and New Combinations
Kathryn Anissa Baksh, Jeffrey S. Weber · 2015 · Seminars in Oncology
YAP regulates PD-L1 expression in human NSCLC cells
Jinbai Miao, Ping‐Chih Hsu, Yi‐Lin Yang, Zhidong Xu, Yuyuan Dai, Yucheng Wang, Geraldine Chan, Zhen Huang, Bin Hu, Hui Li et al. · 2017 · Oncotarget
Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
Maja Šutić, Ana Vukić, Jurica Baranašić, Asta Försti, Feđa Džubur, Miroslav Samaržija, Marko Jakopović, Luka Brčić, Jelena Knežević · 2021 · Journal of Personalized Medicine
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Antoine Millet, Anthony R. Martin, Cyril Ronco, Stéphane Rocchi, Rachid Benhida · 2016 · Medicinal Research Reviews
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome
Joseph Mounir Obeid, Gulsun Erdag, Mark E. Smolkin, Donna H. Deacon, James W. Patterson, Leiping Chen, Timothy N. J. Bullock, Craig Lee Slingluff · 2016 · OncoImmunology
Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy
Sadakatsu Ikeda, Aaron Michael Goodman, Philip R. Cohen, Taylor J. Jensen, Christopher K. Ellison, Garrett Michael Frampton, Vincent A. Miller, Sandip Pravin Patel, Razelle Kurzrock · 2016 · npj Genomic Medicine
Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application
Hongli Gao, Jianqiao Yin, Ce Ji, Xiaopeng Yu, Jinqi Xue, Xin Guan, Shuang Zhang, Xun Liu, Fei Xing · 2023 · Journal of Experimental & Clinical Cancer Research
Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses
Yusuke Kitazawa, Masayuki Fujino, Quanxing Wang, Hiromitsu Kimura, Miyuki Azuma, Masato Kubo, Ryo Abe, Xiaokang Li · 2007 · Transplantation
Orchestrating immune check-point blockade for cancer immunotherapy in combinations
José Luis Perez‐Gracia, Sara Labiano, Maria Esperanza Rodriguez-Ruiz, Miguel F. Sanmamed, Ignacio Melero · 2014 · Current Opinion in Immunology
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
Christian J. Maine, Nor Haslinda Abd Aziz, Jayanta Chatterjee, Claudia Hayford, Nancy Brewig, Lynsey May Whilding, Andrew J.T. George, Sadaf Ghaem‐Maghami · 2013 · Cancer Immunology Immunotherapy
Immunotherapy for the Treatment of Urothelial Carcinoma
Nicholas M. Donin, Andrew Thomas Lenis, Stuart Holden, Alexandra Drakaki, Allan J. Pantuck, Arie S. Belldegrun, Karim Chamie · 2016 · The Journal of Urology
Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
Florine A. Eggink, Inge C. van Gool, Alexandra F. Leary, Pamela M. Pollock, Emma Jayne Crosbie, Linda Mileshkin, Ekaterina S. Jordanova, Julien Adam, Luke Freeman-Mills, David N. Church et al. · 2016 · OncoImmunology
PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Kostandinos Sideras, Katharina Biermann, Joanne Verheij, Robert Bart Takkenberg, Shanta Mancham, Bettina E. Hansen, Hannah M. Schutz, Robert Auke de Man, Dave Sprengers, Sonja I. Buschow et al. · 2017 · OncoImmunology
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
François Bertucci, Anthony Gonçalvès · 2017 · Current Oncology Reports
Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis
Bin Hou, Yao Tang, Wenhan Li, Qingnuo Zeng, Dongmin Chang · 2019 · Disease Markers
ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
Jacob J. Orme, Khalid Jazieh, Tiancheng Xie, Susan M. Harrington, Xin Liu, Matthew K. Ball, Benjamin J. Madden, M. Cristine Charlesworth, Tariq U. Azam, Fabrice Lucien et al. · 2020 · OncoImmunology
The Role of Vascular Cell Adhesion Molecule-1 in Tumor Immune Evasion
T.‐C. Wu · 2007 · Cancer Research
Lumbar disc degeneration is linked to a carbohydrate sulfotransferase 3 variant
You‐Qiang Song, Tatsuki Karasugi, Kmc Cheung, Kazuhiro Chiba, Daniel Wai‐Hung Ho, Atsushi Miyake, Patrick Y.P. Kao, Kit‐Ling Sze, Anita Yee, Atsushi Takahashi et al. · 2013 · Journal of Clinical Investigation
B7-H1 Expression Model for Immune Evasion in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
Odey C. Ukpo, Wade L. Thorstad, James S. Lewis · 2012 · Head and Neck Pathology
Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines
Jingwei Liu, Shurong Zhang, Yuefeng Hu, Zhaomin Yang, J P Li, Xuesong Liu, Lijuan Deng, Yue Wang, Xiaoyan Zhang, Ting Jiang et al. · 2016 · Journal of Immunotherapy
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers
Jian Guan, Khin Sandar Lim, Tarek M. Mekhail, Chung-Che Chang · 2017 · Archives of Pathology & Laboratory Medicine
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Rachel M. Gibbons Johnson, Haidong Dong · 2017 · Frontiers in Immunology
B7-H1 Up-Regulation on Myeloid Dendritic Cells Significantly Suppresses T Cell Immune Function in Patients with Chronic Hepatitis B
Liangen Chen, Zheng Zhang, Weiwei Chen, Zhidong Zhang, Yonggang Li, Ming Shi, Ji‐Yuan Zhang, Lieping Chen, Shengdian Wang, Fu‐Sheng Wang · 2007 · The Journal of Immunology
Apigenin inhibits the inducible expression of programmed death ligand 1 by human and mouse mammary carcinoma cells
Coombs, Melanie R. Power, Harrison, Megan E., Hoskin, David W. · 2016 · Cancer Letters
PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma
Hiroaki Miyoshi, Junichi Kiyasu, Takeharu Kato, Noriaki Yoshida, Joji Shimono, Shintaro Yokoyama, Hiroaki Taniguchi, Yuya Sasaki, Daisuke Kurita, Keisuke Kawamoto et al. · 2016 · Blood
Dual Targeting of Innate and Adaptive Checkpoints on Tumor Cells Limits Immune Evasion
Xiaojuan Liu, Longchao Liu, Zhenhua Ren, Kaiting Yang, Hairong Xu, Yan Luan, Kai Fu, Jingya Guo, Hua Peng, Mingzhao Zhu et al. · 2018 · Cell Reports
CRISPR/Cas9 for Cancer Therapy: Hopes and Challenges
Marta Martínez-Lage, Pilar Puig-Serra, Pablo R. Menéndez, Raúl Torres-Ruiz, Sandra Rodríguez · 2018 · Biomedicines
Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Fausto Petrelli, Giulia Grizzi, Michele Ghidini, Antonio Ghidini, Margherita Ratti, Stefano Panni, Mary Cabiddu, Mara Ghilardi, Karen Borgonovo, Maria Chiara Parati et al. · 2019 · Journal of Immunotherapy
eIF5B drives integrated stress response-dependent translation of PD-L1 in lung cancer
Shruthy Suresh, Beibei Chen, Jingfei Zhu, Ryan J. Golden, Changzheng Lu, Bret M. Evers, Nicole Novaresi, Bethany Smith, Xiaowei Zhan, Vanessa Schmid et al. · 2020 · Nature Cancer
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy
Anastasia Mpakali, Efstratios Stratikos · 2021 · Cancers
p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells
Julia Majewska, Amit Agrawal, Avi Mayo, Lior Roitman, Rishita Chatterjee, Jarmila Sekeresova Kralova, Tomer Landsberger, Yonatan Katzenelenbogen, Tomer Meir-Salame, Efrat Hagai et al. · 2024 · Nature Cell Biology
Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases
Patrick N. Harter, Simon Bernatz, Alexander Scholz, Pia Susann Zeiner, Jenny Zinke, Makoto Kiyose, Stella Blasel, Rudi Beschorner, Christian Senft, Benjamin Bender et al. · 2015 · Oncotarget
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy
François Bertucci, Pascal Finetti, Cécile Colpaert, Émilie Mamessier, Maxime Parizel, Luc Yves Dirix, Patrice Viens, Daniel Birnbaum, Steven Van Laere · 2015 · Oncotarget
PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro
Wanhua Yang, Peter W. Chen, Haochuan Li, HASSAN M. ALIZADEH, Jérry Y. Niederkorn · 2008 · Investigative Ophthalmology & Visual Science
Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.
Zhixue Zheng, Zhaode Bu, Xijuan Liu, Lianhai Zhang, Ziyu Li, Aiwen Wu, Xiaojiang Wu, Xiaojing Cheng, Xiaofang Xing, Hong Du et al. · 2014 · Europe PMC (PubMed Central)
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors
Yu Mei, Wenya Linda Bi, Noah F. Greenwald, Ziming Du, Nathalie Y.R. Agar, Ursula B. Kaiser, Whitney W. Woodmansee, David A. Reardon, Gordon James Freeman, Peter Edward Fecci et al. · 2016 · Oncotarget
Pan-TAM Tyrosine Kinase Inhibitor BMS-777607 Enhances Anti–PD-1 mAb Efficacy in a Murine Model of Triple-Negative Breast Cancer
Canan Kasikara, Viralkumar Davra, David C. Calianese, Ke Geng, Thomas E. Spires, Michael M. Quigley, Michael J. Wichroski, Ganapathy Sriram, Lucía Suárez-López, Michael B. Yaffe et al. · 2019 · Cancer Research
Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine
Yufei He, Guimei Zhang, Xiaohong Wang, Hui Zhang, Ye Yuan, Dong Li, Zuo‐Hua Feng · 2004 · The Journal of Immunology
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Wang, Yu, Sun, Qingguo, Mu, Ning, Sun, Xiaoyang, Wang, Yingying, Fan, Songqing, Su, Ling, Liu, Xiangguo · 2020 · Cell Communication and Signaling
Interaction of B7‐H1 on intrahepatic cholangiocarcinoma cells with PD‐1 on tumor‐infiltrating T cells as a mechanism of immune evasion
Yufu Ye, Lin Zhou, Xiaojun Xie, Guoping Jiang, Haiyang Xie, Shusen Zheng · 2009 · Journal of Surgical Oncology
NKT Cell Networks in the Regulation of Tumor Immunity
Faith C. Robertson, Jay A. Berzofsky, Masaki Terabe · 2014 · Frontiers in Immunology
Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors
Juan Ling Fu, Ian‐James Malm, Deepak K. K. Kadayakkara, Hy Levitsky, Drew M. Pardoll, Young Jin Kim · 2014 · Cancer Research
Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma
Atik Badshah Shaikh, Fangfei Li, Min Li, Bing He, Xiaojuan He, Guofen Chen, Baosheng Guo, Defang Li, Feng Jiang, Lei Dang et al. · 2016 · International Journal of Molecular Sciences
Immunotherapies for malignant glioma
Vassiliki A. Boussiotis, Alain Charest · 2017 · Oncogene
Non-conventional Inhibitory CD4+Foxp3–PD-1hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew David Hellmann, Michael Andrew Postow, Yasin Şenbabaoğlu, Sasikanth Manne, Billel Gasmi, Cailian Liu, Hong Zhong, Yanyun Li et al. · 2018 · Cancer Cell
NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1
Xiaozhen Zhang, Xing Huang, Jian Xu, Enliang Li, Mengyi Lao, Tianyu Tang, Gang Zhang, Chengxiang Guo, Xiaoyu Zhang, Wen Chen et al. · 2021 · Nature Communications
Memory T cells need CD28 costimulation to remember
Alina C. Boesteanu, Peter D. Katsikis · 2009 · Seminars in Immunology
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Dallas B. Flies, Britt J. Sandler, Mario Sznol, Lieping Chen · 2011 · Europe PMC (PubMed Central)
IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells
Sanghoon Lee, S SEO, Byoung Chan Kim, Chang Deok Kim, Ji Hyun Lee, Jian Kang, Pil Jae Maeng, Jong‐Seok Lim · 2005 · Journal of Dermatological Science
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Koichi Ito, Kimberley A. Stannard, Elwyn Gabutero, Amanda M. Clark, Shiyong Neo, Selda Onturk, Helen Blanchard, Stephen John Ralph · 2012 · Cancer and Metastasis Reviews
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers
Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel Paul Normolle, Gordon James Freeman, Daolin Tang, Katie Sue Nason, Jon M. Davison et al. · 2016 · Journal for ImmunoTherapy of Cancer
The expanding role of immunotherapy
Juan Martín-Liberal, María Ochoa de Olza, Cinta Hierro, Alena Gros, Jordi Ahnert Rodon, Josep M. Tabernero · 2017 · Cancer Treatment Reviews
Therapeutic HPV vaccines
Gemma Hancock, Karin Hellner, Lucy Dorrell · 2017 · Best Practice & Research Clinical Obstetrics & Gynaecology
PD-1/PD-L1 in Disease
Nyanbol Kuol, Lily Stojanovska, Kulmira Nurgali, Vasso Apostolopoulos · 2017 · Immunotherapy
Preferential contribution of B7‐H1 to programmed death‐1‐mediated regulation of hapten‐specific allergic inflammatory responses
Fumihiko Tsushima, Hideyuki Iwai, Noriko Otsuki, Masaaki Abe, Sachiko Hirose, Tomohide Yamazaki, Hisaya Akiba, Hideo Yagita∥, Yūzō Takahashi, Ken Omura et al. · 2003 · European Journal of Immunology
Programmed Death-1 Controls T Cell Survival by Regulating Oxidative Metabolism
Victor Tkachev, Stefanie Goodell, Anthony W. Opipari, Ling-Yang Hao, Luigi Franchi, Gary D. Glick, James L.M. Ferrara, Craig Alan Byersdorfer · 2015 · The Journal of Immunology
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
Omid Hamid, Richard D. Carvajal · 2013 · Expert Opinion on Biological Therapy
Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance
Yiting Geng, Hui Wang, LU Chang-qing, Qing Li, Bin Xu, Jingting Jiang, Changping Wu · 2014 · International Journal of Clinical Oncology
B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer
Yixiang Mao, Wei Li, Kai Chen, Yufeng Xie, Qiang Liu, Min Yao, Weiming Duan, Xiumin Zhou, Rongrui Liang, Min Tao · 2014 · Oncotarget
Cancer Immunotherapy: Selected Targets and Small‐Molecule Modulators
Hilmar Weinmann · 2016 · ChemMedChem
Targeting the tumour microenvironment in ovarian cancer
Jean Marie Hansen, Robert Louis Coleman, Anil K. Sood · 2016 · European Journal of Cancer
The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints
Santosha Adipudi Vardhana, Anas Younes · 2016 · Haematologica
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment
Sara Saab, Hussein Zalzale, Zahraa Rahal, Yara Khalifeh, Ansam F. Sinjab, Humam N. Kadara · 2020 · Frontiers in Immunology